Could be that the increased patent activity and complexity is indicating that MYMD-1 is close to demonstrating that it can moderate the progression of Hashimoto's Thyroiditis, a breakthrough that would have very dramatic implications for MYMD Pharmaceutical's outlook! That would be very interesting.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.